This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Mirati Therapeutics Résultats passés
Passé contrôle des critères 0/6
Mirati Therapeutics's earnings have been declining at an average annual rate of -35.9%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 34.7% per year.
Informations clés
-35.9%
Taux de croissance des bénéfices
-26.2%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 34.7% |
Rendement des fonds propres | -76.7% |
Marge nette | -1,900.7% |
Dernière mise à jour des bénéfices | 30 Sep 2023 |
Mises à jour récentes des performances passées
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Ventilation des recettes et des dépenses
Comment Mirati Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Sep 23 | 38 | -726 | 292 | 0 |
30 Jun 23 | 27 | -738 | 281 | 0 |
31 Mar 23 | 19 | -737 | 259 | 0 |
31 Dec 22 | 12 | -741 | 240 | 0 |
30 Sep 22 | 12 | -738 | 213 | 0 |
30 Jun 22 | 78 | -645 | 187 | 0 |
31 Mar 22 | 73 | -634 | 162 | 0 |
31 Dec 21 | 72 | -582 | 137 | 0 |
30 Sep 21 | 74 | -483 | 118 | 0 |
30 Jun 21 | 13 | -491 | 104 | 0 |
31 Mar 21 | 13 | -407 | 94 | 0 |
31 Dec 20 | 13 | -358 | 83 | 0 |
30 Sep 20 | 12 | -329 | 70 | 0 |
30 Jun 20 | 2 | -296 | 61 | 0 |
31 Mar 20 | 2 | -259 | 51 | 0 |
31 Dec 19 | 3 | -213 | 43 | 0 |
30 Sep 19 | 6 | -169 | 37 | 0 |
30 Jun 19 | 5 | -142 | 31 | 0 |
31 Mar 19 | 5 | -125 | 26 | 0 |
31 Dec 18 | 13 | -98 | 22 | 0 |
30 Sep 18 | 9 | -88 | 18 | 0 |
30 Jun 18 | 9 | -77 | 16 | 0 |
31 Mar 18 | 9 | -67 | 15 | 0 |
31 Dec 17 | 0 | -70 | 13 | 0 |
30 Sep 17 | 0 | -72 | 14 | 13 |
30 Jun 17 | 0 | -75 | 15 | 30 |
31 Mar 17 | 0 | -79 | 15 | 48 |
31 Dec 16 | 0 | -83 | 15 | 0 |
30 Sep 16 | 0 | -82 | 15 | 67 |
30 Jun 16 | 0 | -81 | 16 | 66 |
31 Mar 16 | 0 | -75 | 16 | 59 |
31 Dec 15 | 0 | -65 | 16 | 49 |
30 Sep 15 | 0 | -57 | 16 | 41 |
30 Jun 15 | 0 | -46 | 15 | 33 |
31 Mar 15 | 0 | -42 | 14 | 29 |
31 Dec 14 | 0 | -44 | 13 | 26 |
30 Sep 14 | 0 | -45 | 12 | 23 |
30 Jun 14 | 0 | -65 | 12 | 22 |
31 Mar 14 | 0 | -62 | 11 | 19 |
31 Dec 13 | 0 | -53 | 11 | 20 |
30 Sep 13 | 0 | -48 | 10 | 20 |
30 Jun 13 | 0 | -24 | 8 | 19 |
Des revenus de qualité: MRTX is currently unprofitable.
Augmentation de la marge bénéficiaire: MRTX is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: MRTX is unprofitable, and losses have increased over the past 5 years at a rate of 35.9% per year.
Accélération de la croissance: Unable to compare MRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: MRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Rendement des fonds propres
ROE élevé: MRTX has a negative Return on Equity (-76.69%), as it is currently unprofitable.